GOSS PE Ratio & Valuation, Is GOSS Overvalued

Historical Valuation

Gossamer Bio Inc (GOSS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 28.16 is considered Overvalued compared with the five-year average of -2.51. The fair price of Gossamer Bio Inc (GOSS) is between 0.16 to 0.35 according to relative valuation method. Compared to the current price of 0.43 USD , Gossamer Bio Inc By Overvalued By 21.25%.

Relative Value

Fair Zone

0.16-0.35

Current Price：0.43

21.25%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Gossamer Bio Inc (GOSS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Gossamer Bio Inc (GOSS) has a current Price-to-Book (P/B) ratio of -8.09. Compared to its 3-year average P/B ratio of -2.68, the current P/B ratio is approximately 202.40% higher. Relative to its 5-year average P/B ratio of -1.26, the current P/B ratio is about 541.79% higher. Gossamer Bio Inc (GOSS) has a Forward Free Cash Flow (FCF) yield of approximately -23.78%. Compared to its 3-year average FCF yield of -54.44%, the current FCF yield is approximately -56.32% lower. Relative to its 5-year average FCF yield of -46.63%, the current FCF yield is about -49.01% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GOSS competitors is 5.81, providing a benchmark for relative valuation. Gossamer Bio Inc Corp (GOSS.O) exhibits a P/S ratio of 28.16, which is 384.67% above the industry average. Given its robust revenue growth of 47.13%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GOSS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GOSS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GOSS currently overvalued or undervalued?

What is Gossamer Bio Inc (GOSS) fair value?

GOSS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Gossamer Bio Inc (GOSS) is between 0.16 to 0.35 according to relative valuation method.

How does GOSS's valuation metrics compare to the industry average?

The average P/S ratio for GOSS's competitors is 5.81, providing a benchmark for relative valuation. Gossamer Bio Inc Corp (GOSS) exhibits a P/S ratio of 28.16, which is 384.67% above the industry average. Given its robust revenue growth of 47.13%, this premium appears sustainable.

What is the current P/B ratio for Gossamer Bio Inc (GOSS) as of Mar 21 2026?

As of Mar 21 2026, Gossamer Bio Inc (GOSS) has a P/B ratio of -8.09. This indicates that the market values GOSS at -8.09 times its book value.

What is the current FCF Yield for Gossamer Bio Inc (GOSS) as of Mar 21 2026?

As of Mar 21 2026, Gossamer Bio Inc (GOSS) has a FCF Yield of -23.78%. This means that for every dollar of Gossamer Bio Inc's market capitalization, the company generates -23.78 cents in free cash flow.

What is the current Forward P/E ratio for Gossamer Bio Inc (GOSS) as of Mar 21 2026?

As of Mar 21 2026, Gossamer Bio Inc (GOSS) has a Forward P/E ratio of -3.95. This means the market is willing to pay $-3.95 for every dollar of Gossamer Bio Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Gossamer Bio Inc (GOSS) as of Mar 21 2026?

As of Mar 21 2026, Gossamer Bio Inc (GOSS) has a Forward P/S ratio of 28.16. This means the market is valuing GOSS at $28.16 for every dollar of expected revenue over the next 12 months.

GOSS Valuation